Neuronetics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Neuronetics, Inc. (STIM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-17
- Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-12-31 was $100.00K, a 0.00% change year-over-year.
- Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-06-30 was $96.00K, a 93.60% decline year-over-year.
- Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-03-31 was $4.00K, a 99.94% decline year-over-year.
- Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $0.00.
- Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $0.00.
- Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Neuronetics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $200.00K, a 97.56% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-17 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-17 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-17 | |||
| 2022-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $100.00K derived: sum of 2 quarters · filed 2025-03-27 | $196.00K derived: sum of 3 quarters · filed 2025-03-27 | $200.00K 10-K · filed 2025-03-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $96.00K derived: sum of 2 quarters · filed 2022-11-08 | $100.00K 10-Q · filed 2022-11-08 | $200.00K derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-06-30 | $96.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $100.00K 10-Q · filed 2022-08-02 | $200.00K derived: sum of 3 quarters · filed 2024-03-08 | $300.00K derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-03-31 | $4.00K 10-Q · filed 2022-05-12 | $104.00K derived: sum of 2 quarters · filed 2024-03-08 | $204.00K derived: sum of 3 quarters · filed 2024-03-08 | $1.70M derived: sum of 4 quarters · filed 2024-03-08 |
| 2021-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $200.00K derived: sum of 2 quarters · filed 2024-03-08 | $1.70M derived: sum of 3 quarters · filed 2024-03-08 | $8.20M 10-K · filed 2024-03-08 |
| 2021-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.60M derived: sum of 2 quarters · filed 2021-11-09 | $8.10M 10-Q · filed 2021-11-09 | $9.10M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $8.00M 10-Q · filed 2021-08-03 | $9.00M derived: sum of 3 quarters · filed 2023-03-07 | $9.20M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $6.50M 10-Q · filed 2021-05-04 | $7.50M derived: sum of 2 quarters · filed 2023-03-07 | $7.70M derived: sum of 3 quarters · filed 2023-03-07 | $7.82M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $1.20M derived: sum of 2 quarters · filed 2023-03-07 | $1.32M derived: sum of 3 quarters · filed 2023-03-07 | $1.40M 10-K · filed 2023-03-07 |
| 2020-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $320.00K derived: sum of 2 quarters · filed 2020-11-02 | $400.00K 10-Q · filed 2020-11-02 | $600.00K derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $200.00K 10-Q · filed 2020-08-04 | $400.00K derived: sum of 3 quarters · filed 2022-03-08 | $1.60M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $80.00K 10-Q · filed 2020-05-05 | $280.00K derived: sum of 2 quarters · filed 2022-03-08 | $1.48M derived: sum of 3 quarters · filed 2022-03-08 | $4.08M derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $1.40M derived: sum of 2 quarters · filed 2022-03-08 | $4.00M derived: sum of 3 quarters · filed 2022-03-08 | $10.80M 10-K · filed 2022-03-08 |
| 2019-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $3.80M derived: sum of 2 quarters · filed 2019-11-05 | $10.60M 10-Q · filed 2019-11-05 | $13.80M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $9.40M 10-Q · filed 2019-08-06 | $12.60M derived: sum of 3 quarters · filed 2021-03-02 | $12.60M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-03-31 | $6.80M 10-Q · filed 2019-05-07 | $10.00M derived: sum of 2 quarters · filed 2021-03-02 | $10.00M derived: sum of 3 quarters · filed 2021-03-02 | |
| 2018-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $3.20M derived: sum of 2 quarters · filed 2021-03-02 | $3.30M 10-K · filed 2021-03-02 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $100.00K 10-Q · filed 2018-11-06 | ||
| 2018-06-30 | $100.00K 10-Q · filed 2018-08-14 | |||
| 2017-12-31 | $100.00K 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |